StocksAtBottom.com Announces Investment Opinions: Popular Stocks in the News.

Business Editors

NOTE TO EDITORS: The following is an investment opinion issued

by StocksAtBottom.com

WESTPORT, Conn.--(BUSINESS WIRE)--June 19, 2003

StocksAtBottom.com (http://www.StocksAtBottom.com) gives you these stock opinions for the short term:

http://www.StocksAtBottom.com believes that Eastman Kodak (EK:NYSE) will honor its dividend requirement, while Microsoft (MSFT:NASDAQ) will impact its organization with new Infopath software. Oracle (ORCL:NASDAQ) remains a buy due to consolidation in enterprise software markets. Rite Aid (RAD:NYSE) is a buy as fundamentals improve. Pfizer (PFE:NYSE) has five years of growth ahead of it.

http://www.StocksAtBottom.com believes Eastman Kodak will still be able to honor its 45 cents per quarter dividend in spite of its warning that it will only earn 25 cents in the current quarter. With a 5.8 percent dividend yield in place, Kodak will do everything possible to sustain the dividend. The stock is a long-term buy.

http://www.StocksAtBottom.com believes Microsoft will set the world on fire with its new Infopath software. Organizations will now be able to collect and process information differently than was ever possible before Infopath. Standardizing forms within corporations has been an unrealized dream prior to the Microsoft introduction. Information on forms will be managed electronically instead of through paper.

Oracle has upped the ante in its pursuit of PeopleSoft. Regardless of the outcome, Oracle will benefit dramatically from the current consolidation in the enterprise software market.

Rite Aid continues to be under followed by Wall Street while the stock continues to move higher. http://www.StocksAtBottom.com has made money twice before on this stock and continues to like it for at least the next several quarters. The Wall Street Journal reported today on the ex-CEO receiving a jail sentence. The jail sentence has no implications for the current status of the stock.

Pfizer (PFE:NYSE) is trading at 19 times earnings with a 16% compounded sustainable growth rate coming for the next several years. Couple this with a $400 billion dollar government financed drug program for Seniors and you have one powerful stock for the rest of the decade.

Subscribers to http://www.StocksAtBottom.com have seen a 40% compounded growth pattern in their portfolios over the last four years which have included one of the century's worst market environments.

All information presented herein is the opinion of http://www.StocksAtBottom.com. We do not own directly or indirectly any shares in the stocks that are mentioned in this article.